Every material Form 8-K CASTLE BIOSCIENCES INC has filed with the SEC since May 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Castle Biosciences reported third-quarter 2026 revenue of $102.9 million, up from $83.0 million a year earlier, and raised its full-year 2026 revenue guidance to $385-395 million from $365-375 million. The company's net loss widened to $4.1 million, or $0.13 per share, from $0.5 million, or $0.02 per share, in the same period of 2025.
Q3 2026 revenue was $102.9 million, compared with $83.0 million in Q3 2025.
Q3 2026 net loss was $4.1 million, or $0.13 per share, versus $0.5 million, or $0.02 per share, a year earlier.
2026 total revenue guidance raised to $385-395 million from $365-375 million; positive Adjusted EBITDA expected for Q4 2026, full-year 2026 and full-year 2027.
Net cash provided by operations was $19.7 million in Q3 2026 versus $22.6 million a year earlier; cash and marketable investment securities totaled $277.7 million as of Sep. 30, 2026.
Castle Biosciences reported second quarter 2026 revenue of $103.5 million, up from $86.2 million a year earlier, and raised its full-year 2026 revenue guidance to $365-375 million from $345-355 million. The company posted a second-quarter net loss of $2.1 million, compared with net income of $4.5 million in the same period of 2025, so higher sales did not carry through to profit for the quarter.
Q2 2026 revenue was $103.5 million, compared with $86.2 million in Q2 2025.
Q2 2026 net loss was $2.1 million, or $0.07 per share, versus net income of $4.5 million, or $0.15 per diluted share, a year earlier.
2026 total revenue guidance raised to $365-375 million from $345-355 million; company expects positive Adjusted EBITDA in Q3, Q4 and full year 2026.
Cash, cash equivalents and marketable investment securities totaled $266.8 million as of June 30, 2026.
Castle Biosciences reported first-quarter 2026 revenue of $83.7 million, down from $88.0 million a year earlier, and raised its full-year 2026 revenue guidance to $345-355 million from $340-350 million. The net loss narrowed to $14.5 million from $25.8 million, but the prior-year period included a one-time $20.1 million amortization charge, and revenue declined year over year.
Q1 2026 revenue was $83.7 million, compared with $88.0 million in Q1 2025.
Net loss was $14.5 million, or $0.49 per share, versus a net loss of $25.8 million, or $0.90 per share, a year earlier.
2026 total revenue guidance was raised to $345-355 million from $340-350 million.
Cash, cash equivalents and marketable investment securities totaled $261.7 million as of March 31, 2026; net cash used in operations was $22.1 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CASTLE BIOSCIENCES INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →